Floatz logo

MERCAPTOPURINE ANHYDROUS

Acute Myeloid Leukemia By FAB Classification

Roswell Park Cancer InstituteSmall moleculePhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Acute Myeloid Leukemia By FAB Classification cohort.

Asset / SponsorPhaseRating
Daunomycin
Wake Forest University Health Sciences
Phase 3BBB
Idarubicin
University of Nebraska
Phase 3BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BB
Valspodar
National Cancer Institute (NCI)
Phase 3BB
Azacitidine
guomei
Phase 2BB

View all 49 →

Same molecule, other indications

MERCAPTOPURINE ANHYDROUS is also rated in:

adult acute lymphoblastic leukemiaActive
A
Indicative · Phase 4
81 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative · Phase 3
80 / 100
View asset →
childhood acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 3
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →